We are pioneering a new therapeutic approach to treat debilitating ear, nose and throat (ENT) diseases that impact the lives of millions of people.
Our first product candidate targets chronic rhinosinusitis (CRS), which affects about 27 million - 11% of adults - in the U.S., and has no approved pharmaceutical treaments.
Sep 17, 2019 Lyra Therapeutics Adds Vineeta Belanger, Ph.D., as Senior Vice President of Clinical Affairs
Sep 04, 2019 Lyra Therapeutics Appoints Ann Merrifield to its Board of Directors
